



Final Appraisal Recommendation
Advice No: 2017 – October 2017

**Dolutegravir (Tivicay®) 10 mg, 25 mg and 50 mg
film-coated tablets**

Limited submission by ViiV Healthcare UK Ltd

Recommendation of AWMSG

Dolutegravir (Tivicay®) is recommended as an option for use within NHS Wales in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- This advice incorporates and replaces the existing AWMSG recommendation on dolutegravir (Tivicay®) for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age (Advice number 2314, originally published September 2014).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3373), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	ViiV Healthcare UK Ltd
Date of first issue	October 2017
Last reviewed	October 2020

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 2017:
Dolutegravir (Tivicay[®]) 10 mg, 25 mg and 50 mg film coated-tablets. October 2017.

